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cardiac amyloidosis (Fig. 2a, b). After rectal biopsy, amyloid 
light chain (AL) amyloidosis was diagnosed. He was treated 
with diuretics but died 4 months later. At autopsy, primary 
systemic amyloidosis with extensive cardiac involvement 
was confirmed. Gross examination showed a marked increase 
in cardiac mass with atrial dilatation (heart weight 707 g). 
Microscopy revealed extensive deposition of amyloid with 
characteristic perimyocytic, interstitial and vascular distribu-
tion, confirmed by Congo red staining (Fig. 3a, b). Addition-
ally, a plasma cell dyscrasia was found as associated disease.
General discussion
Amyloidosis is characterised by accumulation of insoluble 
proteins (amyloids) in the extracellular space of different 
organs. In AL amyloidosis, the most common form, mis-
folded light chains are produced due to plasma cell dyscra-
sia. Cardiac amyloid infiltration leads to wall thickening and 
diastolic dysfunction, resulting in a restrictive cardiomyop-
athy. The median age at presentation is 60 years. Cardiac 
involvement carries the worst prognosis, with a median sur-
vival of 6 months after the onset of heart failure symptoms 
[1]. The therapeutic goals are the following: (1) treatment 
of heart failure and (2) prevention of progressive amyloid 
deposition. Because beta-blockers and angiotensin-convert-
ing enzyme inhibitors are usually not very well tolerated, 
diuretic therapy is often the sole option to treat heart failure. 
Dexamethasone combined with melphalan, lenalidomide or 
bortezomib may increase survival, but rapid disease onset 
and diagnostic delays contribute to an unfavourable prog-
nosis [2].
Abstract Our case report describes the strong ability of 
noninvasive diagnostic techniques to detect cardiac in-
volvement in advanced systemic amyloid light chain amy-
loidosis, which was confirmed at autopsy.
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A 63-year-old man was admitted with progressive dyspnoea. 
Physical examination revealed dullness on percussion and 
diminished breathing sounds on auscultation of both basal 
lung fields and pitting oedema of the lower extremities. The 
electrocardiogram (ECG) showed sinus rhythm, left atrial dil-
atation, low-voltage QRS complexes in the extremity leads, 
right QRS axis deviation and clockwise rotation with negative 
T waves in V5–6 (Fig. 1a). Echocardiography showed mild 
pericardial but massive pleural effusion, increased biventric-
ular mass, left ventricular ejection fraction (LVEF) 35 % and 
restrictive diastolic function (E/A > 2, E-wave deceleration 
time 90 ms) (Fig. 1b, c). Two-dimensional speckle tracking 
echocardiography showed reduced global longitudinal sys-
tolic strain with relative apical sparing (Fig. 1d). Subsequent 
cardiac magnetic resonance imaging (CMR) showed a typi-
cal delayed enhancement pattern with a dark blood pool and 
globally increased myocardial signal intensity, suggestive of 
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Noninvasive imaging techniques
Endomyocardial biopsy remains the gold standard to diag-
nose cardiac amyloidosis, but is invasive, associated with 
complications and limited to experienced centres. Non-
invasive cardiac imaging techniques have proven to be 
of diagnostic value in combination with a high degree of 
clinical suspicion. The combination of imaging findings of 
increased ventricular wall thickness and low QRS voltages 
in the extremity leads on the ECG has a 72 % sensitivity and 
91 % specificity to diagnose cardiac amyloidosis [3].
Characteristic echocardiographic findings include atrial 
enlargement, increased biventricular mass, increased myo-
cardial echogenecity (‘granular speckling pattern’) and dia-
stolic dysfunction with restrictive physiology in the advanced 
stages of the disease [4]. LVEF may remain normal until late in 
disease, but longitudinal shortening decreases early. Speckle 
tracking echocardiography (STE) can measure global and 
regional longitudinal strain and shows higher apex-to-base 
Fig. 2 Cardiovascular magnetic 
resonance imaging: a Still frame 
of a cine horizontal long-axis 
view, showing ventricular hyper-
trophy and massive bilateral pleu-
ral effusion (Pl. E). b Delayed 
enhancement image in horizontal 
long-axis view obtained 10 min 
after intravenous gadolinium 
administration, showing a typical 
‘cardiac amyloidosis pattern’: 
global myocardial enhancement 
(*) and a dark blood pool (BP)
 
Fig. 1 Electrocardiogram (ECG) and echocardiography: a ECG 
showing sinus rhythm, left atrial dilatation, low QRS voltage in the 
extremity leads, right QRS-axis deviation and clockwise rotation. b 
Two-dimensional echocardiogram: apical four-chamber view showing 
biventricular hypertrophy, left atrial dilatation, pericardial (PE) and 
pleural effusion (Pl. E). c Mitral valve pulsed wave Doppler registra-
tion, showing restrictive diastolic function. d Speckle tracking shows 
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specialised staining techniques, it is possible to differentiate 
between different forms of amyloidosis, such as in this case 
where the amyloid depositions were of the AL type.
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strain values with relative apical sparing in cardiac amyloido-
sis. STE had 93 % sensitivity and 82 % specificity to differen-
tiate cardiac amyloidosis from other hypertrophic myocardial 
diseases in one study (Fig. 1d) [5].
In cardiac amyloidosis, myocardial gadolinium kinet-
ics after intravenous administration is abnormal due to an 
expanded extracellular space. Delayed-enhancement CMR 
commonly shows a global transmural and/or subendocardial 
enhancement pattern in the advanced stages of the disease [6]. 
Characteristic for cardiac amyloidosis is that these delayed-
enhancement patterns are accompanied with a dark appear-
ance of the blood pool (Fig. 2b). Suboptimal nulling and 
patchy focal hyper-enhancement may also be observed, but 
are associated with lesser degrees of amyloid accumulation 
and a better clinical profile [7]. Delayed-enhancement CMR 
has a high diagnostic accuracy to diagnose cardiac amyloido-
sis (sensitivity 88 %, specificity 90 %) and provides prognostic 
information as well [8]. Visual assessment of T1 using a mod-
ified delayed-enhancement CMR pulse sequence is an alter-
native and simple method to identify abnormal myocardial 
tissue: myocardial tissue reaches the null crossing (becomes 
black) at an earlier or same inversion time as the blood pool 
indicating abnormally low myocardial T1 values and hence 
abnormally high myocardial gadolinium uptake [9].
Although nuclear imaging is not a first-line investigation, 
it shows promise to differentiate between cardiac amyloido-
sis subtypes (cardiac AL and transthyretin-related cardiac 
amyloidosis (ATTR, mutant and wild types)), which has 
important therapeutic and prognostic implications [10].
Pathology
Gross inspection findings at autopsy are generally nonspecific 
and may mimic other forms of hypertrophic heart disease, 
such as hypertrophic cardiomyopathy. Atrial enlargement is 
a constant feature, whereas ventricular dilatation is uncom-
mon. Histologically, amyloid deposits can be highlighted 
using various stains, of which Congo red is most commonly 
used for the diagnosis of amyloidosis. Although the origin and 
compositions of the amyloid deposits may vary, their patho-
logical appearance is identical among forms. With the use of 
Fig. 3 Autopsy findings: a 
Intermediate magnification 
micrograph at autopsy, hematoxy-
lin eosin staining (HE) staining 
showing extensive interstitial 
amyloid deposition between car-
diomyocytes as well as vascular 
amyloid deposition. b Congo 
red staining amyloid shows an 
apple-green birefringence under 
polarised light
 
